Bank of America Comments on Eli Lilly

Bank of America has published a report on Eli Lilly & Co LLY. In the report, Bank of America wrote, "A large majority of docs (72%) expect their TRT prescribing to grow over the next year, while the rest expect stable prescribing. Rising patient awareness, testing, and new drugs were frequently cited as growth drivers. In our view, the survey supports the potential for continued strong growth of the TRT market, which has historically grown much faster relative to the overall US Pharma market given low levels of diagnosis and treatment of the condition." Bank of America rated Eli Lilly a BUY with a price target of $43.00. Eli Lilly closed Thursday at $38.00.